The influence of @entity1338 pretreatment on psychopathological, endocrine and respiratory effects of @entity23910 ( @entity23911 ) was characterized. @entity1 with @entity4697 (DSM-III-R) were given 50 micrograms @entity23911 i.v. at 1100 hours on 2 separate study days. In a randomized double-blind design they were additionally infused with 150 micrograms @entity1338 or placebo from 1040 to 1110 hours. After @entity23911 all @entity1 experienced symptom attacks. No effects of @entity1338 on @entity1503 were observed. After @entity23911 , in the @entity1338 condition the pituitary release of @entity3317 (ACTH) and prolactin was seemingly enhanced compared to placebo. Our results suggest that @entity23911 -induced @entity4697 attacks are not suppressible by presynaptic alpha-2 receptor stimulation. Moreover, they point to a synergistic postsynaptic action of @entity1338 to @entity23911 upon pituitary hormone secretion. The diverging sites of action might possibly explain the discrepancies of psychopathological alterations and stress hormone secretion.

Influence of XXXX on psychopathological, endocrine and respiratory effects of @entity23910 in @entity1 with @entity4697 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4697 :: ('MESH:D016584', 'Disease') :: ['panic', 'panic disorder'] @entity23911 :: ('5754', 'Gene') :: ['CCK-4'] @entity23910 :: ('MESH:D013758', 'Chemical') :: ['cholecystokinin tetrapeptide'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['panic psychopathology or blood gas parameters'] @entity3317 :: ('MESH:D000324', 'Chemical') :: ['adrenocorticotropin'] @entity1338 :: ('MESH:D003000', 'Chemical') :: ['clonidine']
@entity1338 :: (MESH:D003000,Chemical) :: ['clonidine']
